Compare ALCO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | LYEL |
|---|---|---|
| Founded | 1960 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.3M | 320.1M |
| IPO Year | 1994 | 2021 |
| Metric | ALCO | LYEL |
|---|---|---|
| Price | $39.56 | $11.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $44.00 | $30.60 |
| AVG Volume (30 Days) | 12.3K | ★ 92.9K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | $30.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.32 | $11.47 |
| 52 Week High | $45.01 | $45.00 |
| Indicator | ALCO | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 35.26 |
| Support Level | $37.31 | $11.59 |
| Resistance Level | $40.01 | $14.14 |
| Average True Range (ATR) | 0.74 | 0.81 |
| MACD | -0.06 | -0.30 |
| Stochastic Oscillator | 18.90 | 4.37 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.